JP2013017486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013017486A5 JP2013017486A5 JP2012221023A JP2012221023A JP2013017486A5 JP 2013017486 A5 JP2013017486 A5 JP 2013017486A5 JP 2012221023 A JP2012221023 A JP 2012221023A JP 2012221023 A JP2012221023 A JP 2012221023A JP 2013017486 A5 JP2013017486 A5 JP 2013017486A5
- Authority
- JP
- Japan
- Prior art keywords
- hematopoietic stem
- protein
- conditionally immortalized
- stem cells
- proto
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 62
- 108090000623 proteins and genes Proteins 0.000 claims 39
- 102000004169 proteins and genes Human genes 0.000 claims 38
- 108700020978 Proto-Oncogene Proteins 0.000 claims 32
- 102000052575 Proto-Oncogene Human genes 0.000 claims 32
- 210000004027 cell Anatomy 0.000 claims 29
- 238000000034 method Methods 0.000 claims 28
- 210000000130 stem cell Anatomy 0.000 claims 22
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 18
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 18
- 230000006907 apoptotic process Effects 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 230000035755 proliferation Effects 0.000 claims 17
- 230000004083 survival effect Effects 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 230000014509 gene expression Effects 0.000 claims 11
- 102000004889 Interleukin-6 Human genes 0.000 claims 9
- 108090001005 Interleukin-6 Proteins 0.000 claims 9
- 229940100601 interleukin-6 Drugs 0.000 claims 9
- 230000004913 activation Effects 0.000 claims 8
- 108010002386 Interleukin-3 Proteins 0.000 claims 7
- 102000000646 Interleukin-3 Human genes 0.000 claims 7
- 230000010261 cell growth Effects 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 239000003102 growth factor Substances 0.000 claims 7
- 102000051485 Bcl-2 family Human genes 0.000 claims 6
- 108700038897 Bcl-2 family Proteins 0.000 claims 6
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims 6
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims 6
- 102000036693 Thrombopoietin Human genes 0.000 claims 6
- 108010041111 Thrombopoietin Proteins 0.000 claims 6
- 229940068935 insulin-like growth factor 2 Drugs 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 101710149951 Protein Tat Proteins 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000012258 culturing Methods 0.000 claims 5
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 4
- 238000004113 cell culture Methods 0.000 claims 4
- 229940029303 fibroblast growth factor-1 Drugs 0.000 claims 4
- 102000003951 Erythropoietin Human genes 0.000 claims 3
- 108090000394 Erythropoietin Proteins 0.000 claims 3
- 230000004069 differentiation Effects 0.000 claims 3
- 229940105423 erythropoietin Drugs 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 239000002609 medium Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 3
- 230000026683 transduction Effects 0.000 claims 3
- 238000010361 transduction Methods 0.000 claims 3
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 claims 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 210000004504 adult stem cell Anatomy 0.000 claims 2
- 108700000711 bcl-X Proteins 0.000 claims 2
- 102000055104 bcl-X Human genes 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000012679 serum free medium Substances 0.000 claims 2
- 230000002463 transducing effect Effects 0.000 claims 2
- -1 Bcl-w Proteins 0.000 claims 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 1
- 101710150912 Myc protein Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000011712 cell development Effects 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 238000003208 gene overexpression Methods 0.000 claims 1
- 230000009395 genetic defect Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000001976 improved effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72813105P | 2005-10-18 | 2005-10-18 | |
| US60/728,131 | 2005-10-18 | ||
| US76599306P | 2006-02-06 | 2006-02-06 | |
| US60/765,993 | 2006-02-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536713A Division JP2009511081A (ja) | 2005-10-18 | 2006-10-18 | 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014108137A Division JP6302356B2 (ja) | 2005-10-18 | 2014-05-26 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013017486A JP2013017486A (ja) | 2013-01-31 |
| JP2013017486A5 true JP2013017486A5 (enExample) | 2014-05-22 |
| JP5726148B2 JP5726148B2 (ja) | 2015-05-27 |
Family
ID=37963171
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536713A Pending JP2009511081A (ja) | 2005-10-18 | 2006-10-18 | 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 |
| JP2012221023A Expired - Fee Related JP5726148B2 (ja) | 2005-10-18 | 2012-10-03 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2014108137A Expired - Fee Related JP6302356B2 (ja) | 2005-10-18 | 2014-05-26 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2016027812A Pending JP2016129515A (ja) | 2005-10-18 | 2016-02-17 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2017166334A Expired - Fee Related JP6655050B2 (ja) | 2005-10-18 | 2017-08-31 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2019006759A Expired - Fee Related JP6797221B2 (ja) | 2005-10-18 | 2019-01-18 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2020119082A Expired - Fee Related JP7078673B2 (ja) | 2005-10-18 | 2020-07-10 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2022025236A Pending JP2022065146A (ja) | 2005-10-18 | 2022-02-22 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536713A Pending JP2009511081A (ja) | 2005-10-18 | 2006-10-18 | 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014108137A Expired - Fee Related JP6302356B2 (ja) | 2005-10-18 | 2014-05-26 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2016027812A Pending JP2016129515A (ja) | 2005-10-18 | 2016-02-17 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2017166334A Expired - Fee Related JP6655050B2 (ja) | 2005-10-18 | 2017-08-31 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2019006759A Expired - Fee Related JP6797221B2 (ja) | 2005-10-18 | 2019-01-18 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2020119082A Expired - Fee Related JP7078673B2 (ja) | 2005-10-18 | 2020-07-10 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2022025236A Pending JP2022065146A (ja) | 2005-10-18 | 2022-02-22 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US8883507B2 (enExample) |
| EP (1) | EP1942739B1 (enExample) |
| JP (8) | JP2009511081A (enExample) |
| KR (2) | KR101441843B1 (enExample) |
| CN (2) | CN101330830B (enExample) |
| AT (1) | ATE491022T1 (enExample) |
| AU (1) | AU2006304392B2 (enExample) |
| CA (2) | CA2626525C (enExample) |
| DE (1) | DE602006018768D1 (enExample) |
| IL (7) | IL286053B2 (enExample) |
| IN (1) | IN2014DN06624A (enExample) |
| WO (1) | WO2007047583A2 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883507B2 (en) | 2005-10-18 | 2014-11-11 | The Regents Of The University Of Colorado | Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells |
| CA2685492C (en) * | 2006-05-31 | 2018-01-16 | The Brigham And Women's Hospital, Inc. | Abcb5 positive mesenchymal stem cells as immunomodulators |
| GB0619500D0 (en) * | 2006-10-03 | 2006-11-08 | Univ Keele | Treatment of fibrosis |
| CA2680613A1 (en) | 2007-03-13 | 2008-09-18 | National Jewish Medical And Research Center | Methods for generation of antibodies |
| SG10201803982TA (en) | 2008-05-16 | 2018-07-30 | Taiga Biotechnologies Inc | Antibodies and processes for preparing the same |
| DK2313496T3 (en) * | 2008-07-21 | 2014-12-15 | Taiga Biotechnologies Inc | Anukleære differentiated cells, and method for preparation thereof |
| US8784825B2 (en) * | 2008-08-28 | 2014-07-22 | Taiga Biotechnologies, Inc. | Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC |
| US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
| ES2796111T3 (es) | 2008-11-14 | 2020-11-25 | Brigham & Womens Hospital Inc | Métodos terapéuticos relacionados con células madre cancerosas |
| SG10201403707QA (en) * | 2009-06-29 | 2014-10-30 | Ilya B Leskov | Non-human mammal model of human hematopoietic cancer |
| BR122013008030B8 (pt) * | 2009-09-15 | 2021-07-27 | Univ Tokyo | método para produzir células eritroides e método para produzir um produto sanguíneo |
| AU2014240253B2 (en) * | 2009-09-15 | 2017-08-03 | The University Of Tokyo | Novel Method for Producing Differentiated Cells |
| WO2011057249A2 (en) | 2009-11-09 | 2011-05-12 | The Brigham And Women's Hospital, Inc. | Treatment of heart disease |
| WO2011138786A2 (en) * | 2010-05-06 | 2011-11-10 | Stem Cell Medicine Ltd. | Stem cell bank for personalized medicine |
| WO2012043651A1 (ja) * | 2010-09-30 | 2012-04-05 | 国立大学法人 熊本大学 | ミエロイド系血液細胞の製造方法 |
| US8889630B2 (en) | 2011-12-23 | 2014-11-18 | Carlos Lopez | Method for hair regrowth using Granulocyte-Colony Stimulating Factor |
| US20130171115A1 (en) * | 2011-12-30 | 2013-07-04 | Gang Li | Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene |
| JP6285930B2 (ja) * | 2012-07-20 | 2018-02-28 | タイガ バイオテクノロジーズ，インク． | 造血コンパートメントの再構築及び自家再構築の増進 |
| ES2860573T3 (es) | 2013-02-19 | 2021-10-05 | Childrens Medical Center | Células madre ABCB5(+) para el tratamiento de enfermedades oculares |
| US9365825B2 (en) * | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| US10272115B2 (en) * | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| BR112015028193B8 (pt) | 2013-05-10 | 2023-04-18 | Childrens Medical Center | Suporte para cicatrização de feridas |
| KR101638403B1 (ko) * | 2013-07-17 | 2016-07-11 | 아주대학교산학협력단 | RGMc를 유효성분으로 포함하는 줄기세포 유도용 배지 조성물 및 이를 이용한 줄기세포의 유도방법 |
| WO2015020993A2 (en) * | 2013-08-05 | 2015-02-12 | The Trustees Of The University Of Pennsylvania | RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA |
| CN103509101B (zh) * | 2013-08-12 | 2016-11-02 | 中国科学院广州生物医药与健康研究院 | 一种扩增脐带血造血干细胞的细胞因子及其培养基 |
| EP3271456A1 (en) | 2015-03-18 | 2018-01-24 | The Regents of the University of California | Methods of preventing and reversing stem cell aging |
| CN106148266A (zh) * | 2015-04-20 | 2016-11-23 | 烟台赛泽生物技术有限公司 | 一种免疫细胞用培养基及该培养基的添加剂 |
| CN104928247B (zh) * | 2015-07-02 | 2018-03-23 | 广州赛莱拉干细胞科技股份有限公司 | 一种神经干细胞培养基及神经干细胞贴壁培养方法 |
| BR112018001232A2 (pt) | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
| SG10201913151TA (en) | 2015-09-09 | 2020-03-30 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Genetic engineering of macrophages for immunotherapy |
| US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| CN105695511B (zh) * | 2016-04-13 | 2025-01-21 | 中国人民解放军第三军医大学 | 一种永生化毛囊干细胞系及其制备方法 |
| CN105713880A (zh) * | 2016-04-20 | 2016-06-29 | 广东艾时代生物科技有限责任公司 | 一种造血干细胞体外扩增培养的无血清培养基及其应用 |
| CN106279403B (zh) * | 2016-08-16 | 2019-06-11 | 长春市海兰深生物医学技术有限公司 | 一种检测天然肺癌相关抗体的组合物、试剂盒和方法 |
| US10583156B2 (en) | 2016-12-02 | 2020-03-10 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| CN106754728B (zh) * | 2016-12-30 | 2020-05-15 | 中国人民解放军总医院 | 后肾间充质细胞系及其制备方法与应用 |
| FR3068366B1 (fr) * | 2017-06-30 | 2023-11-24 | Francais Du Sang Ets | Procede de production de progeniteurs erythroides |
| EP3661953A4 (en) * | 2017-08-03 | 2021-04-14 | Taiga Biotechnologies, Inc. | CANCER TREATMENT METHODS AND COMPOSITIONS |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| US12023357B2 (en) | 2017-10-13 | 2024-07-02 | Hackensack University Medical Center | Rejuvenated aged hematopoietic stem cells and methods of use |
| CN107937342B (zh) * | 2017-11-06 | 2021-07-06 | 中国人民解放军第四军医大学 | 一种通过内皮细胞来源的外泌体扩增神经干细胞的方法 |
| CN108070567A (zh) * | 2018-01-19 | 2018-05-25 | 皓昇莱生物制药有限公司 | 一种永生化的尿液来源细胞株及其构建方法 |
| CA3097875A1 (en) | 2018-04-25 | 2019-10-31 | Children's Medical Center Corporation | Abcb5 ligands and substrates |
| WO2020074925A2 (en) * | 2018-10-12 | 2020-04-16 | Reneuron Limited | Induced pluripotent cell comprising a controllable transgene for conditional immortalisation |
| GB201902068D0 (en) * | 2019-02-14 | 2019-04-03 | Cambridge Entpr Ltd | Methods of reactivating proliferative capacity non-proliferative tissues |
| EP3952909A4 (en) | 2019-04-08 | 2023-06-07 | Taiga Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR CRYOPRESERVING IMMUNE CELLS |
| SG11202112529WA (en) | 2019-05-14 | 2021-12-30 | Taiga Biotechnologies Inc | Compositions and methods for treating t cell exhaustion |
| KR20210012966A (ko) * | 2019-07-24 | 2021-02-03 | 주식회사 에스엘바이젠 | 불사화된 줄기세포주의 제조 방법 및 이의 용도 |
| CN110622921B (zh) * | 2019-09-29 | 2021-06-15 | 江苏大学 | 阿尔茨海默病病变区FoxG1过表达小鼠模型的构建方法及应用 |
| GB202005494D0 (en) * | 2020-04-15 | 2020-05-27 | Reneuron Ltd | Induced pluripotent cell comprising a contollable transgene for conditional immortalisation |
| KR20220057859A (ko) | 2020-10-30 | 2022-05-09 | 전상수 | 펜터리 |
| US20230407268A1 (en) | 2020-11-06 | 2023-12-21 | Trans Chromosomics, Inc. | Method for producing reversibly immortalized cell |
| CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
| EP4365283A4 (en) * | 2021-06-30 | 2025-06-11 | National University Corporation Chiba University | Methods for improving the proliferative properties of common myeloid progenitor cells (CMP) or myelocytic progenitor cells |
| CN113583965A (zh) * | 2021-08-05 | 2021-11-02 | 大连干细胞与精准医学创新研究院 | 一种条件永生化人神经干细胞来源细胞膜纳米囊泡制剂及其制备方法和应用 |
| US20230226116A1 (en) * | 2021-10-20 | 2023-07-20 | University Of Rochester | Method for rejuvenating glial progenitor cells and rejuvenated glial progenitor cells per se |
| CN118973591A (zh) | 2022-03-28 | 2024-11-15 | 合同会社博子科技 | 包含miR-140的药物组合物及其制备方法 |
| CN121022754B (zh) * | 2025-10-27 | 2026-05-29 | 广东普罗凯融生物医药科技有限公司 | 一种健康人脐带血来源的永生化nk细胞系sz093及其制备方法与应用 |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| JPS62501537A (ja) * | 1984-12-21 | 1987-06-25 | テクニクロン・リサ−チ・パ−トナ−ズ・ワン | リンパ球細胞を電気的に不滅化するための方法 |
| DE3531430A1 (de) | 1985-09-03 | 1987-03-05 | Biotest Pharma Gmbh | Verfahren zur gewinnung von komponenten aus einer fluessigkeit mit in raeumlich getrennten bereichen vorliegenden komponenten |
| US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| US4900322A (en) | 1986-09-22 | 1990-02-13 | Adams James D | Blood component pooling valve and kit |
| US5476996A (en) * | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| US5849288A (en) * | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| IE920716A1 (en) | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| AU781922B2 (en) | 1991-12-17 | 2005-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5289858A (en) | 1991-12-18 | 1994-03-01 | Abbott Laboratories | System for accommodating withdrawal of liquid from a bulk supply |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| EP0903408A3 (en) | 1992-08-21 | 2005-11-02 | Biogen, Inc. | Tat-derived transport polypeptide |
| US5580760A (en) | 1993-02-22 | 1996-12-03 | The United States Of America As Represented By The Department Of Health And Human Services | FUSE binding protein and cDNA therefor |
| WO1995003402A1 (en) * | 1993-07-22 | 1995-02-02 | Merck & Co., Inc. | EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL |
| US5599705A (en) * | 1993-11-16 | 1997-02-04 | Cameron; Robert B. | In vitro method for producing differentiated universally compatible mature human blood cells |
| CA2184356A1 (en) | 1994-03-03 | 1995-09-08 | Russell P. Rother | Terminal complement inhibitor fusion genes and proteins |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6713247B1 (en) * | 1996-09-03 | 2004-03-30 | Signal Pharmaceuticials, Inc. | Human CNS cell lines and methods of use therefor |
| ES2210761T3 (es) | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| EP0893493A3 (de) * | 1997-07-21 | 2002-12-04 | Aventis Pharma Deutschland GmbH | Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen |
| GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
| CA2314267A1 (en) | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
| ATE288477T1 (de) | 1998-04-08 | 2005-02-15 | Shionogi & Co | Verfahren um vorläuferzellen von osteoklasten zu isolieren und ihre differenzierung in osteoklasten zu induzieren. |
| US6835567B1 (en) * | 1998-04-14 | 2004-12-28 | Signal Pharmaceuticals, Inc. | PNS cell lines and methods of use therefor |
| US6451558B1 (en) * | 1998-08-03 | 2002-09-17 | Novartis Ag | Genes in the control of hematopoiesis |
| US6913925B1 (en) * | 1998-08-12 | 2005-07-05 | Signal Pharmaceuticals Llc | Human mesencephalon cell lines and methods of use therefor |
| AU7497000A (en) | 1999-02-28 | 2000-11-14 | Washington University | Novel transduction molecules and methods for using same |
| WO2000059540A1 (en) | 1999-04-05 | 2000-10-12 | Biocrystal Ltd. | Assay kits and methods for immune complex-mediated activation involving shed antigens |
| US6358739B1 (en) | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
| US6451601B1 (en) * | 1999-04-12 | 2002-09-17 | Modex Therapeutiques, S.A. | Transiently immortalized cells for use in gene therapy |
| EP1175436B1 (en) * | 1999-04-12 | 2006-10-11 | Heart Biosystems GmbH | Transiently immortalized cells for use in gene therapy |
| US7135287B1 (en) * | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
| US7311920B1 (en) * | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| CA2390011A1 (en) | 1999-11-10 | 2001-05-17 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising renilla gfp |
| EP1103615A1 (en) | 1999-11-25 | 2001-05-30 | Universite De Geneve | Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
| US20010049393A1 (en) * | 1999-12-07 | 2001-12-06 | Whitehead Institute For Biomedical Research | Methods for defining MYC target genes and uses thereof |
| AU2001256746A1 (en) * | 2000-05-15 | 2001-11-26 | Sonoko Habu | Chimeric mouse having immunity constructed by using human cd34-positive cells and use thereof |
| US20020155127A1 (en) | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
| US20030072794A1 (en) * | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| US20070248618A1 (en) * | 2004-03-16 | 2007-10-25 | Cohen David I | Tat-Based vaccine Compositions and Methods of Making and Using Same |
| AU2001296354A1 (en) | 2000-09-25 | 2002-04-02 | Baylor College Of Medicine | Improved system for regulation of transgene expression |
| US20020155502A1 (en) | 2000-10-30 | 2002-10-24 | Horizon Biotechnologies, Inc. | Affinity maturation by competitive selection |
| US20040241140A1 (en) | 2000-11-01 | 2004-12-02 | Pavlakis George N. | Expression vectors able to elicit improved immune response and methods of using same |
| DE60131676T2 (de) * | 2000-12-01 | 2008-10-30 | Central Institute For Experimental Animals | Verfahren zur herstellung einer maus, die für die aufnahme, differenzierung und proliferation von heterogenen zellen geeignet ist, die hierdurch hergestellte maus und ihre verwendung |
| WO2002057436A2 (en) | 2001-01-19 | 2002-07-25 | Gendel Limited | Red blood cell from a transgenic animal as vehicle for polypeptide delivery |
| US7033744B2 (en) | 2001-03-16 | 2006-04-25 | Naoya Kobayashi | Method for proliferating a liver cell, a liver cell obtained thereby, and use thereof |
| WO2002097050A2 (en) * | 2001-05-31 | 2002-12-05 | Novartis Ag | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
| PT1421115E (pt) | 2001-08-31 | 2005-07-29 | Avidex Ltd | Receptor de celulas t soluvel |
| CN1408850A (zh) * | 2001-09-18 | 2003-04-09 | 王虹 | 人血树突状细胞永生化技术 |
| CN100506978C (zh) | 2001-09-21 | 2009-07-01 | 中国人民解放军军事医学科学院野战输血研究所 | 一种新的造血干/祖细胞的富集方法及其体外定向诱导分化 |
| GB0124391D0 (en) | 2001-10-11 | 2001-11-28 | Gene Expression Technologies L | Control of gene expression |
| JP2005508171A (ja) | 2001-11-02 | 2005-03-31 | タノックス インコーポレーテッド | Ｂ細胞悪性病変の診断及び予防に用いるためのｂ細胞リンパ腫特異抗原 |
| EP1321034A1 (en) * | 2001-12-21 | 2003-06-25 | Pfizer Products Inc. | Disruption of the phosphodieterase 10 gene |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| AU2003216288B2 (en) | 2002-02-13 | 2009-09-24 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
| CN1240439C (zh) | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | 肿瘤基因开关药物 |
| US7211191B2 (en) | 2004-09-30 | 2007-05-01 | Thermogenesis Corp. | Blood component separation method and apparatus |
| JP2005523012A (ja) * | 2002-04-16 | 2005-08-04 | デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド | 癌モデル |
| GB2387599B (en) * | 2002-04-17 | 2005-08-10 | Jason Peter Brown | Methods for producing antibodies |
| US7097841B2 (en) * | 2002-05-10 | 2006-08-29 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
| CN1325512C (zh) * | 2002-05-16 | 2007-07-11 | 巴法里安诺迪克有限公司 | Hiv调节/辅助蛋白的融合蛋白 |
| CA2485939C (en) * | 2002-05-29 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| EP1408114B1 (de) * | 2002-10-11 | 2007-01-03 | Imvision GmbH | Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen |
| US20060154331A1 (en) * | 2002-10-15 | 2006-07-13 | Nili Avidan | Erythrocyte differentiation factor, gene encoding same, and methods of use thereof |
| EP2048159B1 (en) | 2002-11-09 | 2014-01-01 | Immunocore Ltd. | T cell receptor display |
| CA2508052A1 (en) | 2002-12-05 | 2004-06-17 | Imperial College Innovations Limited | Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| WO2004084805A2 (en) | 2003-03-19 | 2004-10-07 | The J. David Gladstone Institutes | Acetylated tat polypeptides and methods of use thereof |
| WO2004104185A1 (en) | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
| WO2005014785A2 (en) | 2003-06-18 | 2005-02-17 | The George Washington University | Conditionally-immortalized hematopoietic progenitor cell lines |
| US20060222657A1 (en) | 2003-06-20 | 2006-10-05 | Dowdy Steven F | Polypeptide transduction and fusogenic peptides |
| IL161903A0 (en) | 2003-07-17 | 2005-11-20 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs |
| US7705049B2 (en) * | 2004-01-21 | 2010-04-27 | New York University | Methods for treating non-melanoma cancers with PABA |
| JP2005232148A (ja) | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | 神経保護剤としてプロパルギルアミンの使用 |
| NZ550815A (en) | 2004-05-19 | 2009-04-30 | Immunocore Ltd | Method of improving T cell receptors |
| WO2005113595A2 (en) | 2004-05-19 | 2005-12-01 | Avidex Ltd | High affinity ny-eso t cell receptor |
| EP1791865B1 (en) | 2004-06-29 | 2010-07-28 | Immunocore Ltd. | Cells expressing a modified t cell receptor |
| US20060068469A1 (en) | 2004-08-17 | 2006-03-30 | Research Development Foundation | Bacterial vector systems |
| GB0420963D0 (en) | 2004-09-21 | 2004-10-20 | Reneuron Ltd | Hepatocyte |
| WO2006045064A2 (en) * | 2004-10-20 | 2006-04-27 | Whitehead Institute For Biomedical Research | Cultured hematopoietic stem cells and method for expansion and analysis thereof |
| WO2007067183A1 (en) | 2005-12-09 | 2007-06-14 | The Regents Of The University Of California | Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells |
| US20060156422A1 (en) * | 2005-01-10 | 2006-07-13 | Medical Research Council | Methods and compositions for the generation of antibodies |
| JP2008535823A (ja) | 2005-03-25 | 2008-09-04 | キュラジェン コーポレイション | テネイシンの主要な抗原に対する抗体 |
| WO2006116512A1 (en) | 2005-04-26 | 2006-11-02 | The Board Of Trustees Of The University Of Illinois, Urbana, Il | Nucleoside compounds and methods of use thereof |
| WO2006125962A2 (en) | 2005-05-25 | 2006-11-30 | Medigene Limited | T cell receptors which specifically bind to vygfvracl-hla-a24 |
| JP5276982B2 (ja) * | 2005-08-26 | 2013-08-28 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | オキシトシンの投与による頭痛の処置のための方法 |
| US20070047583A1 (en) | 2005-08-29 | 2007-03-01 | Siemens Aktiengesellschaft | Method for using a short address in a packet header |
| US8883507B2 (en) | 2005-10-18 | 2014-11-11 | The Regents Of The University Of Colorado | Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells |
| AU2006311725B2 (en) * | 2005-11-04 | 2011-11-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of NAV1.8 gene |
| EP1792627A1 (en) | 2005-12-05 | 2007-06-06 | ImVisioN AG | Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| EP2087000A2 (en) | 2006-09-29 | 2009-08-12 | Immunocore Ltd. | T cell therapies |
| CA2680613A1 (en) | 2007-03-13 | 2008-09-18 | National Jewish Medical And Research Center | Methods for generation of antibodies |
| WO2009059304A2 (en) | 2007-11-02 | 2009-05-07 | Taiga Biotechnologies, Inc. | Compounds for treating abnormal cellular proliferation |
| JP5951254B2 (ja) | 2008-03-17 | 2016-07-13 | ザ スクリプス リサーチ インスティテュート | 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法 |
| SG10201803982TA (en) | 2008-05-16 | 2018-07-30 | Taiga Biotechnologies Inc | Antibodies and processes for preparing the same |
| EP2304035A2 (en) | 2008-06-13 | 2011-04-06 | Life & Brain GmbH | Fusion protein and use thereof |
| DK2313496T3 (en) | 2008-07-21 | 2014-12-15 | Taiga Biotechnologies Inc | Anukleære differentiated cells, and method for preparation thereof |
| US8784825B2 (en) | 2008-08-28 | 2014-07-22 | Taiga Biotechnologies, Inc. | Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC |
| EP3031907B1 (en) | 2008-11-06 | 2021-01-06 | Indiana University Research and Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
| CN102272153B (zh) | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
| WO2011100477A2 (en) | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| US20120107317A1 (en) | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| NZ702108A (en) | 2012-05-03 | 2016-09-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
| DE102012209673A1 (de) | 2012-06-08 | 2013-12-24 | Artcline Gmbh | Verfahren zum Herstellen einer Leukozytenpräparation und Leukozytenpräparation |
| JP6285930B2 (ja) | 2012-07-20 | 2018-02-28 | タイガ バイオテクノロジーズ，インク． | 造血コンパートメントの再構築及び自家再構築の増進 |
| NZ741124A (en) | 2012-07-27 | 2019-11-29 | Univ Illinois | Engineering t-cell receptors |
| US20140109246A1 (en) | 2012-09-24 | 2014-04-17 | The Regents Of The University Of Colorado, A Body Corporate | Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species |
| GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| JP6257655B2 (ja) | 2013-03-01 | 2018-01-10 | アメリカ合衆国 | 末梢血から腫瘍反応性ｔ細胞の濃縮された集団を作製する方法 |
| WO2014133567A1 (en) | 2013-03-01 | 2014-09-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
| US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| KR20160145186A (ko) | 2014-04-24 | 2016-12-19 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
| JP6743022B2 (ja) | 2014-12-24 | 2020-08-19 | ネクシミューン インコーポレイテッド | 免疫療法のためのナノ粒子組成物及び方法 |
| EP3402814B1 (en) | 2016-01-15 | 2021-04-21 | Berkeley Lights, Inc. | Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
-
2006
- 2006-10-18 US US11/583,970 patent/US8883507B2/en active Active
- 2006-10-18 JP JP2008536713A patent/JP2009511081A/ja active Pending
- 2006-10-18 KR KR1020137028338A patent/KR101441843B1/ko not_active Expired - Fee Related
- 2006-10-18 IL IL286053A patent/IL286053B2/en unknown
- 2006-10-18 AT AT06826025T patent/ATE491022T1/de active
- 2006-10-18 EP EP06826025A patent/EP1942739B1/en active Active
- 2006-10-18 DE DE602006018768T patent/DE602006018768D1/de active Active
- 2006-10-18 IL IL296832A patent/IL296832A/en unknown
- 2006-10-18 WO PCT/US2006/040379 patent/WO2007047583A2/en not_active Ceased
- 2006-10-18 IN IN6624DEN2014 patent/IN2014DN06624A/en unknown
- 2006-10-18 CA CA2626525A patent/CA2626525C/en active Active
- 2006-10-18 KR KR1020087011791A patent/KR101441693B1/ko not_active Expired - Fee Related
- 2006-10-18 CA CA3065947A patent/CA3065947C/en active Active
- 2006-10-18 AU AU2006304392A patent/AU2006304392B2/en not_active Ceased
- 2006-10-18 CN CN200680045545.8A patent/CN101330830B/zh not_active Expired - Fee Related
- 2006-10-18 CN CN201510760532.XA patent/CN105483088B/zh not_active Expired - Fee Related
-
2008
- 2008-04-17 IL IL190946A patent/IL190946A/en active IP Right Grant
-
2010
- 2010-02-05 US US12/701,383 patent/US9150831B2/en active Active
-
2012
- 2012-10-03 JP JP2012221023A patent/JP5726148B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-30 IL IL224494A patent/IL224494B/en active IP Right Grant
-
2014
- 2014-05-26 JP JP2014108137A patent/JP6302356B2/ja not_active Expired - Fee Related
- 2014-10-08 US US14/509,870 patent/US9796961B2/en not_active Expired - Fee Related
-
2015
- 2015-10-02 US US14/873,296 patent/US20160040129A1/en not_active Abandoned
-
2016
- 2016-02-17 JP JP2016027812A patent/JP2016129515A/ja active Pending
-
2017
- 2017-08-31 JP JP2017166334A patent/JP6655050B2/ja not_active Expired - Fee Related
- 2017-12-24 IL IL256512A patent/IL256512B/en active IP Right Grant
-
2018
- 2018-07-23 US US16/042,904 patent/US10760055B2/en active Active
-
2019
- 2019-01-18 JP JP2019006759A patent/JP6797221B2/ja not_active Expired - Fee Related
- 2019-04-14 IL IL266009A patent/IL266009B/en active IP Right Grant
-
2020
- 2020-06-15 US US16/901,956 patent/US20200308545A1/en not_active Abandoned
- 2020-07-10 JP JP2020119082A patent/JP7078673B2/ja not_active Expired - Fee Related
- 2020-11-02 IL IL278426A patent/IL278426B/en unknown
-
2022
- 2022-01-27 US US17/586,196 patent/US20220145253A1/en not_active Abandoned
- 2022-02-22 JP JP2022025236A patent/JP2022065146A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240417681A1 (en) | Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis | |
| Tanigawa et al. | Selective in vitro propagation of nephron progenitors derived from embryos and pluripotent stem cells | |
| Schaefer et al. | SOX2 and p53 expression control converges in PI3K/AKT signaling with versatile implications for stemness and cancer | |
| CN101330830B (zh) | 条件无限增殖化长期干细胞和制备和使用所述细胞的方法 | |
| Wang et al. | Targeting cancer stem cells: emerging role of Nanog transcription factor | |
| JP7048977B2 (ja) | コロニー形成培地及びその使用 | |
| JPWO2017221975A1 (ja) | Ｃｄ４ｃｄ８両陽性ｔ細胞の製造方法 | |
| CN108291196B (zh) | 表达ets转录因子的工程化的内皮细胞 | |
| US7427603B2 (en) | Method of enhancing proliferation and/or hematopoietic differentiation of stem cells | |
| JP7298858B2 (ja) | 髄核細胞マスターレギュレーター転写因子を含む分化誘導剤、誘導髄核細胞の製造方法、および誘導髄核細胞の用途 | |
| EP3130668A1 (en) | In-vitro expansion of erythroid cells | |
| JPWO2018143243A1 (ja) | 人工多能性幹細胞の作製方法 | |
| Zach et al. | Production and functional characterization of murine osteoclasts differentiated from ER-Hoxb8-immortalized myeloid progenitor cells | |
| Hai‐Jiang et al. | Expansion of hematopoietic stem/progenitor cells | |
| JP7388755B2 (ja) | 髄核前駆細胞マスターレギュレーター転写因子を含む分化誘導剤、誘導髄核前駆細胞の製造方法、および誘導髄核前駆細胞の用途 | |
| US20230272348A1 (en) | Methods of generating hematopoietic cell preparations | |
| Hung et al. | Negative regulation of the differentiation of Flk2− CD34− LSK hematopoietic stem cells by EKLF/KLF1 | |
| CN116479041A (zh) | 一种基因构建体以及产生多谱系造血干祖细胞的方法 | |
| JP6817633B2 (ja) | 造血幹細胞増幅誘導剤 | |
| Singh et al. | Stage-Specific Regulation of Erythropoiesis and Its Implications in Ex-Vivo RBCs Generation. | |
| KR101341558B1 (ko) | 고밀도 배양을 이용한 적혈구계 세포의 인 비트로 확장방법 | |
| JPWO2005056778A1 (ja) | 造血幹細胞の分化抑制又は増殖方法 | |
| KR102414138B1 (ko) | Wnt 단백질 활성 증진용 배지 조성물 | |
| WO2024143555A1 (ja) | 細胞分化度の調節方法 | |
| WO2021107117A1 (ja) | 多能性幹細胞からの造血細胞の製造法 |